264 related articles for article (PubMed ID: 35971106)
1. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma.
Liu J; Brown RE
Int J Clin Exp Pathol; 2010 Oct; 3(8):755-62. PubMed ID: 21151388
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
5. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
7. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
8. Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes.
Fan YL; Li XQ
Clin Endocrinol (Oxf); 2015 Aug; 83(2):261-7. PubMed ID: 25158596
[TBL] [Abstract][Full Text] [Related]
9. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
10. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
[TBL] [Abstract][Full Text] [Related]
11. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
13. uPA receptor expression in benign and malignant thyroid tumors.
Kim SJ; Shiba E; Taguchi T; Tsukamoto F; Miyoshi Y; Tanji Y; Takai S; Noguchi S
Anticancer Res; 2002; 22(1A):387-93. PubMed ID: 12017319
[TBL] [Abstract][Full Text] [Related]
14. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
[TBL] [Abstract][Full Text] [Related]
15. Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.
Němčíková P; Brunerová L
Vnitr Lek; 2023; 69(5):312-315. PubMed ID: 37827829
[TBL] [Abstract][Full Text] [Related]
16. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
17. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]